Exiqon A/S
Press release

Exiqon reminds shareholders of deadline for acceptance of the takeover offer from QIAGEN N.V.

Copenhagen, 2016-05-04 11:24 CEST (GLOBE NEWSWIRE) -- A unanimous Board of Directors of Exiqon A/S recommends the company's shareholders to accept the takeover offer from QIAGEN of DKK 18 per share. Exiqon hereby reminds shareholders that the deadline for acceptance of the offer is 18 May 2016.

On Exiqon's webpagewww.exiqon.com/investorshareholders can find answers to frequently asked questions, including the following:

Question:Will my acceptance prevent me from accepting a higher from another potential buyer?

Answer:No, in that case shareholders are free to accept the higher offer.

Question:What happens if QIAGEN does not reach the 90% acceptance threshold and therefore chooses to cancel the takeover offer?

Answer:Then Exiqon will face a number of challenges, which were discussed at the recent meetings held with the company's shareholders about the takeover offer. A summary of the meetings is attached and available on Exiqon's webpage.

Question:Can I sell my shares for DKK 18 if QIAGEN's offer is cancelled?

Answer:No, the share price will then be determined by supply and demand on the stock exchange.

Additional information

LarsKongsbak, CEO, Telephone +45 4566 0888(cell:+4540902101)

Hans HenrikChroisChristensen,CFO, Telephone +45 4566 0888(cell:+4540902131)

About Exiqon

At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon's research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visitwww.exiqon.com

Exiqon A/S published this content on 04 May 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 04 May 2016 09:28:01 UTC.

Original documenthttps://cns.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=710224&messageId=889366

Public permalinkhttp://www.publicnow.com/view/B37852E28EB6131E3A9693277E53C1FD74041678